File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1080/17512433.2019.1567327
- Scopus: eid_2-s2.0-85060928844
- PMID: 30621472
- WOS: WOS:000457422900006
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Novel developments of hepatitis B: treatment goals, agents and monitoring tools
Title | Novel developments of hepatitis B: treatment goals, agents and monitoring tools |
---|---|
Authors | |
Keywords | Antiviral therapy cirrhosis core protein allosteric modulator covalently closed circular DNA cure genome editing global elimination HBV RNA hepatitis B core-related antigen hepatitis B virus hepatocellular carcinoma immunomodulator integrated DNA prevention programmed cell death protein 1 RNA interfering gene silencer therapeutic vaccine vaccination viral entry inhibitor |
Issue Date | 2019 |
Publisher | Taylor & Francis. The Journal's web site is located at http://www.tandfonline.com/loi/ierj20#.VgGhakaFOnI |
Citation | Expert Review of Clinical Pharmacology, 2019, v. 12 n. 2, p. 109-120 How to Cite? |
Abstract | Introduction: Chronic hepatitis B (CHB) infection causes considerable morbidity and mortality and hence should be a target for global elimination. In recent years, advances have been made in understanding the disease pathophysiology and the relationship to clinical outcome. Novel treatment targets are actively being sought in the hope of improving the treatment outlook.
Areas covered: We discussed the cascade of cure of CHB with respect to the degree of persistence of viral genome and proteins. Several novel antiviral agents either targeting the virus or the host are in different clinical phases of development. Serum hepatitis B core-related antigen and HBV RNA are novel markers, which might have a role in the prediction of specific clinical outcomes such as development of hepatocellular carcinoma or virological relapse after cessation of antiviral therapy. These markers may also be used to monitor treatment response in the drug trials.
Expert commentary: Global elimination of CHB is challenged by extremely low awareness of illness and poor access to care. CHB and its related complications can be reduced by birth dose vaccine, antiviral therapy, and alleviated by complication screening. Treatment options for CHB will expand in the next decade and early functional cure is not an impractical goal. |
Persistent Identifier | http://hdl.handle.net/10722/267450 |
ISSN | 2023 Impact Factor: 3.6 2023 SCImago Journal Rankings: 0.990 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mak, LY | - |
dc.contributor.author | Seto, WKW | - |
dc.contributor.author | Fung, JYY | - |
dc.contributor.author | Yuen, RMF | - |
dc.date.accessioned | 2019-02-18T09:02:18Z | - |
dc.date.available | 2019-02-18T09:02:18Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Expert Review of Clinical Pharmacology, 2019, v. 12 n. 2, p. 109-120 | - |
dc.identifier.issn | 1751-2433 | - |
dc.identifier.uri | http://hdl.handle.net/10722/267450 | - |
dc.description.abstract | Introduction: Chronic hepatitis B (CHB) infection causes considerable morbidity and mortality and hence should be a target for global elimination. In recent years, advances have been made in understanding the disease pathophysiology and the relationship to clinical outcome. Novel treatment targets are actively being sought in the hope of improving the treatment outlook. Areas covered: We discussed the cascade of cure of CHB with respect to the degree of persistence of viral genome and proteins. Several novel antiviral agents either targeting the virus or the host are in different clinical phases of development. Serum hepatitis B core-related antigen and HBV RNA are novel markers, which might have a role in the prediction of specific clinical outcomes such as development of hepatocellular carcinoma or virological relapse after cessation of antiviral therapy. These markers may also be used to monitor treatment response in the drug trials. Expert commentary: Global elimination of CHB is challenged by extremely low awareness of illness and poor access to care. CHB and its related complications can be reduced by birth dose vaccine, antiviral therapy, and alleviated by complication screening. Treatment options for CHB will expand in the next decade and early functional cure is not an impractical goal. | - |
dc.language | eng | - |
dc.publisher | Taylor & Francis. The Journal's web site is located at http://www.tandfonline.com/loi/ierj20#.VgGhakaFOnI | - |
dc.relation.ispartof | Expert Review of Clinical Pharmacology | - |
dc.rights | This is an electronic version of an article published in [include the complete citation information for the final version of the article as published in the print edition of the journal]. [JOURNAL TITLE] is available online at: http://www.informaworld.com/smpp/ with the open URL of your article. | - |
dc.subject | Antiviral therapy | - |
dc.subject | cirrhosis | - |
dc.subject | core protein allosteric modulator | - |
dc.subject | covalently closed circular DNA | - |
dc.subject | cure | - |
dc.subject | genome editing | - |
dc.subject | global elimination | - |
dc.subject | HBV RNA | - |
dc.subject | hepatitis B core-related antigen | - |
dc.subject | hepatitis B virus | - |
dc.subject | hepatocellular carcinoma | - |
dc.subject | immunomodulator | - |
dc.subject | integrated DNA | - |
dc.subject | prevention | - |
dc.subject | programmed cell death protein 1 | - |
dc.subject | RNA interfering gene silencer | - |
dc.subject | therapeutic vaccine | - |
dc.subject | vaccination | - |
dc.subject | viral entry inhibitor | - |
dc.title | Novel developments of hepatitis B: treatment goals, agents and monitoring tools | - |
dc.type | Article | - |
dc.identifier.email | Seto, WKW: wkseto@hku.hk | - |
dc.identifier.email | Fung, JYY: jfung@hkucc.hku.hk | - |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | - |
dc.identifier.authority | Seto, WKW=rp01659 | - |
dc.identifier.authority | Fung, JYY=rp00518 | - |
dc.identifier.authority | Yuen, RMF=rp00479 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1080/17512433.2019.1567327 | - |
dc.identifier.pmid | 30621472 | - |
dc.identifier.scopus | eid_2-s2.0-85060928844 | - |
dc.identifier.hkuros | 296778 | - |
dc.identifier.volume | 12 | - |
dc.identifier.issue | 2 | - |
dc.identifier.spage | 109 | - |
dc.identifier.epage | 120 | - |
dc.identifier.isi | WOS:000457422900006 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 1751-2433 | - |